Bio-Reference Laboratories (BRLI.DL) investors had a great day today, with the stock up 22% after announcing first-quarter earnings. Bio-Reference beat estimates on both the top and bottom lines, although earnings per share still declined year-over-year. Is the company poised to keep succeeding, particularly given the current environment of health care austerity?
In the video below, health care analyst Michael Douglass identifies three key takeaways from the company's earnings report and what investors should be watching for going forward.
